Forces in Motion: Igniting Small-Cap Potential (BIOR, CGTX, DPRO, LGVN, VCNX)

10/27/20247 min read

In the world of stock investing, spotting under-the-radar small-cap companies can lead to impressive gains. These emerging businesses succeed by leveraging a blend of critical drivers. Today, we highlight five standout small-cap stocks, exploring the unique factors fueling their growth and capturing investor interest.

Biora Therapeutics, Inc. (NASDAQ: BIOR) - Biora Therapeutics, Inc. shares closed last week’s trading session up 11%, finishing at $3.90. At the end of September, the company announced it would present a poster at the American College of Gastroenterology (ACG) Annual Scientific Meeting, scheduled for October 29, 2024, from 10:30 AM to 4:00 PM ET in Philadelphia. Notably, the submission received a prestigious Presidential Poster Award from the ACG Abstract Selection Committee—an honor given to fewer than 5% of accepted abstracts each year for their high-quality, novel, and unique research. This month, Biora also announced that CEO Adi Mohanty will present on the company’s 00-size BioJet™ device at the 14th Annual Partnership Opportunities in Drug Delivery (PODD) conference, held in Boston on October 28, 2024, from 3:30 to 3:45 PM ET. “As part of our development efforts, we successfully reduced the size of the BioJet device from 000 to 00, while slightly increasing its payload capacity,” said Mohanty. “Market research shows a strong preference among patients and our pharmaceutical partners for the 00-size device. We're excited about the progress we've made with this innovative, needle-free, liquid injection technology in a smaller, patient-friendly capsule.” Looking ahead, we’ll be monitoring for further updates and watching for a potential breakout above $4.20 with higher trading volume.

--

Cognition Therapeutics, Inc. (NASDAQ: CGTX) - Cognition Therapeutics, Inc. shares closed last week at $0.56, down 4%. In August, the company reported its second-quarter financial results, ending June 30, 2024, and provided a business update. "We shared favorable results from the Phase 2 'SHINE' study, demonstrating proof-of-concept that CT1812 may slow the progression of mild-to-moderate Alzheimer's disease after just six months of treatment," said Lisa Ricciardi, president and CEO of Cognition. "Looking ahead, we are eager to see the results from our 'SHIMMER' study in mild-to-moderate dementia with Lewy bodies by the end of 2024, and we are actively planning the next phase of development in our Alzheimer's program." This month, the company announced that Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will give an oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference on October 29, 2024, at 5:55 PM local time. "Dr. Woodward will present results from pre-specified analyses, providing a comprehensive view of the positive outcomes from the Phase 2 'SHINE' trial of CT1812 in mild-to-moderate Alzheimer's disease," said Anthony O. Caggiano, MD, PhD, Cognition’s chief medical officer and head of R&D. "The consistent efficacy signals observed over six months of treatment, along with a favorable safety profile, strengthen our commitment to advancing CT1812 as a treatment for mild-to-moderate Alzheimer's disease." As we await further updates, we’ll be monitoring for a potential breakout above $0.61 with increased trading volume.

--

Draganfly Inc. (NASDAQ: DPRO) - Draganfly Inc. shares closed last week’s trading session slightly down, slipping just over 1% to $2.66. In September, the company announced it had been selected by a major oil and gas company to develop a fully automated UAS solution for infrastructure monitoring. This project represents a key step in using advanced remote sensing technology to boost operational efficiency and safety in the oil and gas sector. The first phase, involving sensor validation and selection, has been completed, with demonstration and in-field testing scheduled to continue through the end of the year. In future phases, Draganfly’s APEX Drone will integrate with Nightingale Security’s Drone-in-a-Box flight software, known for its industry-leading automation in security applications. This integration will provide a fully automated remote sensing system, enabling the oil and gas company to monitor infrastructure in remote, hazardous, and RF-challenged environments, ensuring continuous surveillance and rapid issue detection. This month, Draganfly announced its participation in the upcoming Wings of Saskatchewan event, taking place in Regina from October 30-31, 2024. The company will showcase its latest drone technology and join discussions with aviation stakeholders on industry trends, safety, and regulatory challenges. "We’re excited to participate in the Wings of Saskatchewan event and present our latest innovations to industry leaders," said Cameron Chell, CEO of Draganfly. "This is a valuable opportunity to discuss key industry trends, airspace safety, and regulatory issues. It also allows us to demonstrate how Draganfly’s technology can drive collaboration across fixed-wing, helicopter, and RPAS sectors, transforming operations in challenging environments like those found in Saskatchewan." In addition to its presentation, Draganfly will exhibit its newest UAV systems, including the APEX Drone and the Commander 3XL, both known for their versatility, autonomy, and interoperability. Conference attendees will have the opportunity to explore these cutting-edge technologies and their applications in surveying, environmental monitoring, and search-and-rescue missions. As we await further updates, we’ll be monitoring for a potential resistance break at $2.80, accompanied by increased trading volume.

--

Longeveron Inc. (NASDAQ: LGVN) - Longeveron Inc. shares closed last week’s trading session up over 6%, finishing at $2.21. This month, the company announced that its submission, titled "Long-term Transplant-free Survival Is Improved in Hypoplastic Left Heart Syndrome with Cell-based Therapy," has been selected for oral presentation at the 51st Annual Meeting of the Congenital Heart Surgeons' Society (CHSS) on Sunday, October 27, 2024. "We are thrilled to present this five-year survival data from our ELPIS I follow-on study at the CHSS meeting, a premier forum for congenital heart disease research," said Wa'el Hashad, CEO of Longeveron. "Based on these promising results, we are advancing our ELPIS II Phase 2b trial, which evaluates Lomecel-B™ as a potential adjunct therapy for treating HLHS. If successful, this trial could pave the way for a BLA submission to seek regulatory approval for Lomecel-B™." Additionally, Longeveron announced that its submission, "Lomecel-B Inhibition of MMP14 Activity Predicts Lomecel-B Bioactivity in the Treatment of Mild Alzheimer's Disease," has been accepted as a late-breaking poster presentation at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24), taking place in Madrid, Spain, from October 29 to November 1, 2024. "We are excited to share key Lomecel-B™ data at CTAD24, a leading event in Alzheimer’s research," said Hashad. "These findings provide valuable mechanistic and clinical insights into the development of cellular therapies for Alzheimer's disease." As we monitor further developments, we’ll be watching for a potential breakout above $2.30, which could signal upward momentum with increased trading volume.

--

Vaccinex, Inc. (NASDAQ: VCNX) - Vaccinex, Inc. shares closed last week slightly down at $3.38. The company recently announced it will present promising new efficacy and safety data from its randomized, double-blind, Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer’s disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid on October 31, 2024. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP of Discovery and Translational Medicine, will deliver the results in a podium presentation. Vaccinex scientists previously identified and published that Semaphorin 4D (SEMA4D), a molecule that binds to plexin-B1 receptors on astrocytes in the brain, is significantly upregulated in stressed or damaged neurons as Alzheimer’s disease progresses. The SIGNAL-AD study is testing the hypothesis that blocking SEMA4D with the pepinemab antibody can inhibit astrocyte receptor signaling, potentially slowing or preventing the harmful effects of astrocyte activation. The company has previously reported that blocking SEMA4D protects healthy astrocyte functions and slows disease progression in patients with Huntington’s disease. Notably, some approved treatments for neurodegenerative conditions have been associated with inflammation and microhemorrhages by compromising brain vasculature. Vaccinex will share new preclinical evidence at CTAD suggesting that pepinemab may offer protective benefits for brain vasculature. As we await further updates, we’ll be watching for a potential resistance break around the $3.55 level, accompanied by increased trading volume. Wewould also like to highlight that the company's S-3 filing became effective on October 25th.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.